Try our Advanced Search for more refined results

Par Pharma Says Its New Drug Won't Rip Off GSK's Lamictal

By Lisa Ryan ( November 19, 2014, 7:18 PM EST) -- Par Pharmaceutical Inc. on Wednesday urged a Pennsylvania federal court to declare that its new drug doesn't infringe GlaxoSmithKline LLC's epilepsy and bipolar disorder treatment Lamictal, saying the U.S. Food and Drug Administration won't let Par market its drug until a generic version of Lamictal is released....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections

Case Information

Case Title

Subscribers Only

Case Number

Subscribers Only

Court

Subscribers Only

Nature of Suit

Subscribers Only

Judge

Subscribers Only

Date Filed

Subscribers Only

Companies

Government Agencies

Patents

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!